Study Review: Empagliflozin and Health QoL outcomes in HFrEF

Reducing symptoms and improving physical functioning are primary goals of heart failure (HF) management that directly impact patient quality of life. The effect novel HF therapies have on health status across the spectrum of disease severity therefore needs to be determined so that patients can understand how therapies will make them feel, alongside any reductions in mortality and hospitalisation risk. This publication summarises a secondary analysis of the EMPEROR-Reduced trial that evaluated both the relationship between health status and the benefits of empagliflozin on clinical outcomes in patients with HF with reduced ejection fraction (HFrEF) and the effects of empagliflozin on health status. This review is sponsored by an educational grant from Boehringer Ingelheim and Eli Lilly.

A free full-text PDF of the paper, Butler J, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur. Heart J. 2021;42(13):1203-1212 is available here.